Figures & data
Abbreviations: BTZ, bortezomib; CTRL, control; i.v., intravenously; p.o., orally; s.c., subcutaneously.
Note: Data presented as mean plus or minus standard deviation.
Abbreviations: BTZ-fu, bortezomib-fake-manipulated but untreated; Bupre, buprenorphine; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; ws, weeks.
Abbreviations: BTZ-fu, bortezomib-fake-manipulated but untreated; Bupre, buprenorphine; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; ws, weeks.
Notes:
aMean values plus or minus standard deviation; *Significantly different from CTRL (P < 0.001).
Abbreviations: BTZ-fu, bortezomib-fake-manipulated but untreated; Bupre, buprenorphine; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; ws, weeks.
Abbreviations: BTZ-fu, bortezomib-fake-manipulated but untreated; Bupre, buprenorphine; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; ws, weeks.
Note: Data presented as mean values plus or minus standard deviation.
Abbreviations: Bupre, buprenorphine; CR 20, CR4056 at 20 mg/kg/day; CR 6, CR4056 at 6 mg/kg/day; CR 60, CR4056 at 60 mg/kg/day; sec, second.
Abbreviations: Bupre, buprenorphine; CR 20, CR4056 at 20 mg/kg/day; CR 6, CR4056 at 6 mg/kg/day; CR 60, CR4056 at 60 mg/kg/day; sec, second.
Notes:
aExp 1: P < 0.001 for BTZ + CR4056 20 and 60 compared with BTZ-fu at day 1; P < 0.05 for BTZ + Bupre and BTZ + CR4056 6 compared with BTZ-fu at day 1; P < 0.001 for BTZ + CR4056 6, 20 and 60 compared with BTZ-fu at day 3; P < 0.05 BTZ + CR4056 6 compared with BTZ-fu at days 7 and 14. bExp 2: P < 0.01 for BTZ + CR4056 2 and 6 compared with BTZ-fu at day 1; P < 0.05 for BTZ + CR4056 0.6 compared with BTZ-fu at day 1; P < 0.01 for BTZ + CR4056 2 and 6 compared with BTZ-fu at day 4; P < 0.05 for BTZ + CR4056 0.6 and BTZ + Gaba compared with BTZ-fu at day 4; P < 0.05 for BTZ + CR4056 6 compared with BTZ-fu at day 14; P < 0.01 for BTZ + CR4056 6 compared with BTZ-fu at day 21. cExp 3: P < 0.05 for all groups co-treated with CR4056 and BTZ (BTZ-CR4056, BTZ-CR4056 2ws, BTZ-CR4056 4ws), as compared with BTZ, starting from days 0, 7, and 21, respectively.
Abbreviations: admin, administration; BTZ-fu, bortezomib-fake-manipulated but untreated; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; IV, intravenously; OS, orally; tiw, three times a week; ws, weeks.
Abbreviations: admin, administration; BTZ-fu, bortezomib-fake-manipulated but untreated; CR4056 0.6, CR4056 at 0.6 mg/kg/day; CR4056 2, CR4056 at 2 mg/kg/day; CR4056 20, CR4056 at 20 mg/kg/day; CR4056 6, CR4056 at 6 mg/kg/day; CR4056 60, CR4056 at 60 mg/kg/day; Gaba, gabapentin; IV, intravenously; OS, orally; tiw, three times a week; ws, weeks.
Notes: Results are expressed as mean of three independent experiments (percentage of cell survival, mean plus or minus standard deviation, with respect to the control); control value was set as 100%; **Significantly different from control (P < 0.01); ***Significantly different from control (P < 0.001); #Significantly different from BTZ (P < 0.01).
Abbreviation: DMSO, dimethyl sulfoxide.
Abbreviation: DMSO, dimethyl sulfoxide.